General Information of DTT (ID: TTL53M6)

DTT Name Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DTT Info
Gene Name MCL1

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Patented Agent(s)
Investigative Drug(s)
7 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Obatoclax DMPF9ZM Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
ABBV-467 DM87SM9 Multiple myeloma 2A83 Phase 1 [2]
AMG 176 DM0Q7NO Acute myeloid leukaemia 2A60 Phase 1 [3]
AMG 397 DM7CNTG Refractory hematologic malignancy 2A85.5 Phase 1 [4]
AZD5991 DM7QGHO Haematological malignancy 2B33.Y Phase 1 [3]
MIK665 DMTUVCG Acute myeloid leukaemia 2A60 Phase 1 [5]
PRT1419 DMIKE0O Melanoma 2C30 Phase 1 [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Clinical Trial Drug(s)
22 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Biphenyl carboxylic acid derivative 1 DMPWFJN N. A. N. A. Patented [7]
Biphenyl carboxylic acid derivative 2 DM6TXF4 N. A. N. A. Patented [7]
Indole-based analog 1 DMIGS81 N. A. N. A. Patented [7]
Indole-based analog 2 DM0NEVC N. A. N. A. Patented [7]
Indole-based analog 3 DMTEYQJ N. A. N. A. Patented [7]
PMID27744724-Compound-10 DMFKS2P N. A. N. A. Patented [7]
PMID27744724-Compound-13 DMCFOXP N. A. N. A. Patented [7]
PMID27744724-Compound-18 DM73S2C N. A. N. A. Patented [7]
PMID27744724-Compound-19 DM214WA N. A. N. A. Patented [7]
PMID27744724-Compound-20 DMD0T6S N. A. N. A. Patented [7]
PMID27744724-Compound-21 DM18UA5 N. A. N. A. Patented [7]
PMID27744724-Compound-22 DMM6FOW N. A. N. A. Patented [7]
PMID27744724-Compound-23 DMXA70C N. A. N. A. Patented [7]
PMID27744724-Compound-26 DM8GOH3 N. A. N. A. Patented [7]
PMID27744724-Compound-27 DMV6MLC N. A. N. A. Patented [7]
PMID27744724-Compound-28 DMB018S N. A. N. A. Patented [7]
PMID27744724-Compound-29 DM2GDXH N. A. N. A. Patented [7]
PMID27744724-Compound-3 DMWKYU4 N. A. N. A. Patented [7]
PMID27744724-Compound-4 DMV1WND N. A. N. A. Patented [7]
PMID27744724-Compound-5 DM6UTAQ N. A. N. A. Patented [7]
PMID27744724-Compound-6 DMV7P4N N. A. N. A. Patented [7]
PMID27744724-Compound-Fomula2 DMT2W97 N. A. N. A. Patented [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 22 Patented Agent(s)
2 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
BITHIONOL DMPJKRL Trematode infection 1F8Y Withdrawn from market [8]
Sch-45752 DME9Q3V Asthma CA23 Terminated [8]
------------------------------------------------------------------------------------
13 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
ALTENUSIN DMYCS0B Discovery agent N.A. Investigative [8]
AMENTOFLAVONE DMLRNV2 Discovery agent N.A. Investigative [8]
EU-517 DMZ1FCJ Solid tumour/cancer 2A00-2F9Z Investigative [9]
GNF-PF-1591 DMHCGBZ Discovery agent N.A. Investigative [8]
GNF-PF-3955 DMOJL61 Discovery agent N.A. Investigative [8]
GNF-PF-5134 DM7850H Discovery agent N.A. Investigative [8]
MORIN DM2OGZ5 Discovery agent N.A. Investigative [8]
NSC-180246 DMXBRCI Discovery agent N.A. Investigative [8]
NSC-66209 DMQ0S4B Discovery agent N.A. Investigative [8]
QEDIIRNIARHLAQVGDSMDR DMJ38YV Discovery agent N.A. Investigative [10]
ROSMARINIC ACID DMQ6SJT Rheumatoid arthritis FA20 Investigative [8]
SULFURETIN DMYPM2D Discovery agent N.A. Investigative [8]
TW-37 DMDE8YS Discovery agent N.A. Investigative [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Investigative Drug(s)
Molecule Interaction Atlas

References

1 Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
2 Clinical pipeline report, company report or official report of AbbVie.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of Amgen.
5 MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
6 Clinical pipeline report, company report or official report of Prelude Therapeutics.
7 Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
8 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2847).
10 Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42.